| Company Name: |
Shanghai Chaolan Chemical Technology Center
|
| Tel: |
021-QQ：65489617 15618227136 |
| Email: |
Sales@ATKchemical.com |
| Products Intro: |
Product Name:(Rac)-ErSO-DFP
CAS:2768139-73-5
Purity:98% Package:50MG;100MG,1G,5G,100G
|
| Company Name: |
SuZhou GoodChemTech Co., Ltd
|
| Tel: |
18136139868; 18136139868 |
| Email: |
jinlun@goodchemtech.cn |
| Products Intro: |
Product Name:(Rac)-ErSO-DFP
CAS:2768139-73-5
Purity:98% Remarks:10g
|
| Company Name: |
TargetMol Chemicals Inc.
|
| Tel: |
15002134094 |
| Email: |
marketing@targetmol.cn |
| Products Intro: |
Product Name:(Rac)-ErSO-DFP
CAS:2768139-73-5
Package:100mg/RMB 17500;25mg/RMB 10600;50mg/RMB 13800
|
2H-Indol-2-one, 3-(4,4-difluoro-1-piperidinyl)-1,3-dihydro-3-(4-hydroxyphenyl)-7-(trifluoromethyl)- manufacturers
- (Rac)-ErSO-DFP
-
- $2500.00 / 100mg
-
2025-10-27
- CAS:2768139-73-5
- Min. Order:
- Purity:
- Supply Ability: 10g
|
| | 2H-Indol-2-one, 3-(4,4-difluoro-1-piperidinyl)-1,3-dihydro-3-(4-hydroxyphenyl)-7-(trifluoromethyl)- Basic information |
| | 2H-Indol-2-one, 3-(4,4-difluoro-1-piperidinyl)-1,3-dihydro-3-(4-hydroxyphenyl)-7-(trifluoromethyl)- Chemical Properties |
| Boiling point | 485.1±45.0 °C(Predicted) | | density | 1.49±0.1 g/cm3(Predicted) | | pka | 9?+-.0.30(Predicted) |
| | 2H-Indol-2-one, 3-(4,4-difluoro-1-piperidinyl)-1,3-dihydro-3-(4-hydroxyphenyl)-7-(trifluoromethyl)- Usage And Synthesis |
| Uses | (Rac)-ErSO-DFP is a derivative of ErSO-DFP and a selective small molecule Erα biomodulator. (Rac)-ErSO-DFP againsts ERα+ breast cancer (including resistant tumors) by hyperactiving the Erα-dependent a-UPR (extracted from patent WO2022087234A1)[1]. | | in vivo | (Rac)-ErSO-DFP (compound 2) (5 mg/kg; i.v.; 3xq.wk.) shows a sustained activity of againsting ERα+ breast cancer at low doses[1]. | Animal Model: | Ovariectomized Nu/J mice (MCF-7 orthotopic tumor model)[1]. | | Dosage: | 5 mg/kg | | Administration: | Intravenous injection; once-a-week for 3 total doses. | | Result: | Maintained the ability to regress MCF-7 tumors in a mouse model of ERα+ breast cancer. |
| | References | [1] Hergenrother, et al. Enzyme-activating compounds and compositions. Patent WO2022087234A1. |
| | 2H-Indol-2-one, 3-(4,4-difluoro-1-piperidinyl)-1,3-dihydro-3-(4-hydroxyphenyl)-7-(trifluoromethyl)- Preparation Products And Raw materials |
|